Granting of AdaptVac’s HER2 cancer vaccine patent in the United States

09. september 2018   |   AdaptVac  |  Flere pressemeddelelser

Hørsholm, Denmark, September 10, 2018 – AdaptVac announces allowance of its U.S. divisional patent application “Virus-like particle with efficient epitope display" by the USPTO. The divisional patent provides intellectual property protection for the U.S. market of AdaptVac’s novel vaccine targeting HER2-positive cancer (AV001). Furthermore, allowance of the divisional patent in the U.S. validates the patentability of AdaptVac’s virus-like particle technology platform patent portfolio.

 

 

Granting of our HER2 vaccine patent in the world’s largest oncology market represents enormous value to AdaptVac. We are therefore delighted by this decision and the support it affords our future AV001 clinical development and fundraising activities”, says Dr. Wian de Jongh, AdaptVac’s CEO.

 


Strong worldwide market potential in breast cancer

Breast cancer is a widespread oncology indication affecting more than 1.3 million worldwide annually, resulting in more than 450,000 deaths (Tao, 2015: www.ncbi.nlm.nih.gov/pubmed/25543329). The most common treatment today is based on monoclonal antibodies, where the dominating therapy HERCEPTIN (trastuzumab) generates annual global sales of US$ 7 billion. The target product profile of AdaptVac's lead breast cancer project is tailored to be highly competitive both in terms of cost and efficacy, thus aiming at a significant market share.

 

About AdaptVac ApS 

AdaptVac is a joint venture between ExpreS2ion Biotechnologies and NextGen Vaccines, combining ExpreS2ion’s platform with novel proprietary and ground-breaking virus-like particle (VLP) technology developed at the University of Copenhagen. The Company aims to accelerate the development of highly efficient therapeutic and prophylactic vaccines within high value segments of oncology, infectious diseases and immunological disorders.

 

This press release was submitted for publication through the agency of the contact person set out below on September 10, 2018.